SOP for trial initiation ICF management –> – Clinical Research Made Simple https://www.clinicalstudies.in Trusted Resource for Clinical Trials, Protocols & Progress Sat, 09 Aug 2025 23:42:37 +0000 en-US hourly 1 https://wordpress.org/?v=6.9.1 SOP for Informed Consent Process in Clinical Trials https://www.clinicalstudies.in/sop-for-informed-consent-process-in-clinical-trials/ Sat, 09 Aug 2025 23:42:37 +0000 ]]> https://www.clinicalstudies.in/sop-for-informed-consent-process-in-clinical-trials/ Read More “SOP for Informed Consent Process in Clinical Trials” »

]]>
SOP for Informed Consent Process in Clinical Trials

{
“@context”: “https://schema.org”,
“@type”: “Article”,
“mainEntityOfPage”: {
“@type”: “WebPage”,
“@id”: “https://www.Clinicalstudies.in/SOP-for-Informed-Consent-Process-in-Clinical-Trials”
},
“headline”: “SOP for Informed Consent Process in Clinical Trials”,
“description”: “This SOP outlines the regulatory-compliant informed consent process in clinical trials, including preparation, documentation, witness requirements, and special provisions for vulnerable populations, as per ICH GCP, WHO, FDA, EMA, and CDSCO guidelines.”,
“author”: {
“@type”: “Organization”,
“name”: “ClinicalStudies.in”
},
“publisher”: {
“@type”: “Organization”,
“name”: “ClinicalStudies.in”,
“logo”: {
“@type”: “ImageObject”,
“url”: “https://www.clinicalstudies.in/logo.png”
}
},
“datePublished”: “2025-08-26”,
“dateModified”: “2025-08-26”
}

Standard Operating Procedure for Informed Consent Process in Clinical Trials

Department Clinical Research
SOP No. CR/ICF/011/2025
Supersedes NA
Page No. 1 of 23
Issue Date 26/08/2025
Effective Date 01/09/2025
Review Date 01/09/2026

Purpose

The purpose of this SOP is to establish a standardized informed consent process for clinical trials, ensuring that participants or their legally authorized representatives are adequately informed about the nature of the trial, potential risks, benefits, and their rights. This process ensures compliance with ICH-GCP, WHO, FDA, EMA, and CDSCO guidelines and safeguards the autonomy and welfare of trial participants.

Scope

This SOP applies to all investigators, sub-investigators, clinical research coordinators, and trial staff responsible for obtaining informed consent in clinical trials conducted under the Clinical Research Department. It also applies to situations requiring re-consent or electronic consent.

Responsibilities

  • Principal Investigator (PI): Ensures the informed consent process is conducted properly and in compliance with applicable regulations.
  • Sub-Investigator/Study Coordinator: Assists in explaining study procedures and obtaining consent.
  • Witness (if required): Signs the consent form when a participant is illiterate or unable to read.
  • Quality Assurance Officer: Reviews consent records during audits to verify compliance.
  • Head of Clinical Research: Provides oversight and approves SOP implementation.

Accountability

The Principal Investigator is accountable for ensuring that no trial-related procedure is performed before obtaining valid informed consent. The PI must also ensure appropriate documentation and safe custody of signed informed consent forms (ICFs).

Procedure

1. Preparation of Informed Consent Form (ICF)
Draft ICFs in accordance with ICH GCP and regulatory requirements.
Translate ICFs into local languages where necessary.
Obtain EC/IRB approval for all versions of the ICF before use.

2. Conduct of Informed Consent Process
Provide potential participants sufficient time to read and understand the ICF.
Explain the purpose, procedures, risks, benefits, rights, and confidentiality protections.
Allow participants to ask questions freely before signing.
Ensure participants understand that participation is voluntary and withdrawal is possible at any time.

3. Documentation of Consent
Obtain signatures of participant (or legal representative), PI/sub-investigator, and witness (if applicable).
Record date and time of consent.
Provide participant with a signed copy of the ICF.
File original ICF securely in site trial records.

4. Re-Consent Process
Re-consent participants if new safety information emerges, protocol is amended, or ICF content changes.
Conduct re-consent in the same manner as initial consent, with signatures and dates documented.

5. Electronic Consent (eConsent)
Use validated electronic systems that meet regulatory requirements (FDA 21 CFR Part 11, EMA guidelines).
Ensure participant identity is verified and audit trails are maintained.

6. Archiving
Store ICFs in a secure, access-controlled environment.
Retain records for minimum of 5 years post trial completion or as per regulatory requirement.

Abbreviations

  • SOP: Standard Operating Procedure
  • ICF: Informed Consent Form
  • PI: Principal Investigator
  • EC: Ethics Committee
  • IRB: Institutional Review Board
  • QA: Quality Assurance
  • eConsent: Electronic Consent

Documents

  1. ICF Template (Annexure-1)
  2. Informed Consent Process Checklist (Annexure-2)
  3. Consent Documentation Log (Annexure-3)

References

  • ICH E6(R2) Good Clinical Practice
  • US FDA 21 CFR Part 50 – Informed Consent Regulations
  • EMA Guidance on Electronic Consent
  • WHO Guidelines on Informed Consent
  • CDSCO Clinical Trial Rules, 2019

Version: 1.0

Approval Section

Prepared By Rajesh Kumar, Clinical Research Coordinator
Checked By Sunita Reddy, QA Officer
Approved By Dr. Anil Sharma, Principal Investigator

Annexures

Annexure-1: ICF Template

Section Description
Study Title [Insert Title]
Purpose Explain trial objectives
Procedures Details of trial-related procedures
Risks/Benefits Outline possible risks and benefits
Confidentiality Describe data protection measures

Annexure-2: Informed Consent Process Checklist

Step Completed (Yes/No) Remarks
Participant given ICF copy Yes Signed version provided
Discussion of risks and benefits Yes Documented in log
Questions addressed Yes Clarified by PI

Annexure-3: Consent Documentation Log

Date Participant ID Version of ICF Witness Name Investigator Name
05/09/2025 PAT-001 V1.0 Ravi Kumar Dr. Meera Joshi

Revision History

Revision Date Revision No. Revision Details Reason for Revision Approved By
26/08/2025 00 Initial version New SOP creation Head, Clinical Research

For more SOPs visit: Pharma SOP

]]>